VaxiAm Group is an animal health technology development company that builds bridges between research labs and commercial entities in the U.S. and China and transforms innovative ideas to successful products. Our passion is to transform animal health discoveries into commercial products through partnerships with technology inventors and pharmaceutical companies.
Bridges need a strong foundation.
This is ours.
Bridges need to be made from the strongest materials.
This is what we are made of.
Thousands of innovative ideas are patented each year by animal health researchers in universities; however, only a very small portion of them are transformed into commercial products due to limited partnership between academic inventors and private industry. Obtaining innovative technologies and products are increasingly important for animal health companies in emerging markets such as China.
Who We Are
VaxiAm Group and its team of intellectual property brokers and analysts are experts in transforming animal health research into commercial products in the U.S. and China. We are skilled in identifying novel technologies with great commercial value, and uniquely positioned to bridge the gap between academic research institutions in the U.S. and animal health companies in China.
What We Do
VaxiAm Group teams are specialized in research fields such as animal health biologicals and pharmaceuticals, biopharmaceuticals, veterinary diagnostics, feed additives, and companion animals care technologies and products. We identify and evaluate IP assets in these fields and find business partners in China and/or the U.S. that are willing to co-develop, license, or purchase these technologies for commercialization in the China animal health market.